SignalTech/AI
Early progress on accelerating drug development with Claude
Claude shows early progress accelerating drug development, signaling AI traction in pharma R&D.
Context
What happened: Anthropic's life sciences team said it has partnered with six organizations on drug development work using Claude, including BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, and has begun drug discovery efforts of its own.
Key numbers: Divergence Labs generated roughly 35,000
Why it matters: Anthropic said the work has already led it to prioritize specific model improvements, and that the programs can serve as case studies for the wider life sciences community. It plans to scale the work up substantially.
What changed
Anthropic's life sciences team said it has partnered with six organizations on drug development work using Claude, including BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, and has begun drug discovery efforts of its own.
Why it matters
Anthropic said the work has already led it to prioritize specific model improvements, and that the programs can serve as case studies for the wider life sciences community. It plans to scale the work up substantially.